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Epithelial to Mesenchymal transition (EMT) in cancer, a process permitting cancer cells to become mobile and
metastatic, has a signaling hardwire forged from development. Multiple signaling pathways that regulate
carcinogenesis enabling characteristics in neoplastic cells such as proliferation, resistance to apoptosis and
angiogenesis are also the main players in EMT. These pathways, as almost all cellular processes, are in their turn
regulated by ubiquitination and the Ubiquitin-Proteasome System (UPS). Ubiquitination is the covalent link of target
proteins with the small protein ubiquitin and serves as a signal to target protein degradation by the proteasome or
to other outcomes such as endocytosis, degradation by the lysosome or specification of cellular localization. This
paper reviews signal transduction pathways regulating EMT and being regulated by ubiquitination.
Keywords: Epithelial to mesenchymal transition, Ubiquitination, Ubiquitin-proteasome system, Signal transduction,
CarcinogenesisIntroduction
Epithelial to Mesenchymal transition (EMT) describes
the process that allows an epithelial cell belonging in an
epithelial membrane to detach from its neighbors, to
transverse the dissolving basement membrane and move
through the extra-cellular matrix to other sites of the tis-
sue or even to distant organs. In order to facilitate mo-
bility during EMT, connections joining the cell to
adjacent epithelial cells are dissolved [1]. Concomitantly,
the cell acquires a fibroblast-like shape, down-regulates
epithelial markers and up-regulates mesenchymal mar-
kers. EMT is a process that physiologically takes place
during development. Multi-cellular organisms derive
their variety of specialized cells and tissues from a single
cell, the fertilized ovum. This cell has to differentiate to
the three layers of differentiation, the ectoderm, meso-
derm and endoderm and further to different tissues and
cell types in complex but ordered patterns. During de-
velopment EMT takes place as an integral process of dif-
ferentiation to the various cell types in a highlyCorrespondence: ivoutsadakis@yahoo.com
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reproduction in any medium, provided the orregulated in space and time manner. For example during
embryonal gastrulation the epiblast layer produces a
midline invagination, the primitive streak, from which
cells are mobilized by undergoing an EMT and produce
the mesoderm and endoderm. In another developmental
example, dorsal neural tube-derived neural crest cells
undergo an EMT and migrate to form components of
the peripheral nervous system, skin melanocytes, adrenal
medulla and facial bones and muscles [2].
Derived from a single cell, all cells of a multi-cellular
organism possess the same DNA sequences in their
whole genome and thus their various phenotypes must
be the result of differences in transcriptional and post-
transcriptional regulation of cellular proteins secondary
to intra-cellular and external signals. Post-translational
modifications can regulate function, localization and
turn-over of every cell protein impacting on cell morph-
ology, activity and interactions in the multi-cellular or-
ganism. Ubiquitination is such a post-translational
modification. Ubiquitination is the covalent attachment
of molecules of the small 76 amino-acids protein ubiqui-
tin to a target protein which is then marked for prote-
asome destruction or endocytosis or participation in a
range of processes. Ubiquitination along with othertd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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phosphorylation, hydroxylation and acetylation is a regu-
lated process for the execution of which a multitude of
regulators exist. Many signal transducers and transcrip-
tion factors involved in EMT are regulated by ubiquiti-
nation and the ubiquitin proteasome system. This review
will discuss EMT signal transduction pathways and rela-
tionship with Ubiquitin-Proteasome system (UPS) while
the extensive network of transcription factors regulating
EMT and their relationship to UPS will not be discussed
here.
EMT in cancer
EMT is proposed to happen in three different scenarios
with different starting points and outcomes. In develop-
ment EMT is used by normal fetal cells for obtaining
the different specificities present in the multi-cellular or-
ganism. In adult tissue injury repair, EMT is used to heal
open wounds and may lead to fibrosis. In a third sce-
nario, EMT happens during the tissue invasion and
metastatic process of malignant epithelial cells. These
three EMT types have recently been labelled by conven-
tion type 1, 2 and 3 [3]. The starting point of type 1
EMT is, thus, epithelial progenitors in the embryo that
lose conduct with their initial site and move to become
a different structure with different morphology and
function. In type 2 EMT, epithelial cells of an injured
site lose conduct with their neighbours to move and be-
come fibroblasts contributing to injury repair but also
possibly to pathologic fibrosis. Cancer associated EMT
or type 3 EMT endows epithelial cancer cells with the
ability to detach from their initial site, pass through the
resolving basement membrane into adjacent tissues and
even metastasize to distant sites. In vitro and in vivo cri-
teria for the confirmation of EMT have been established
and fall into two broad categories [4]. First, they include
up-regulation of specific mesenchymal markers and
down-regulation of epithelial-associated proteins. Sec-
ond, they describe general cell properties of the new cell
state. Mesenchymal proteins induced in EMT include
S100A4 [also called FSP1(Fibroblast-Specific Protein 1)],
vimentin, type I collagen and its receptor kinase DDR2Figure 1 The ubiquitination cascade. E1 denotes ubiquitin-activating en
ubiquitin.(Discoidin Domain Receptor tyrosine kinase 2), cadherin
N and OB, transcription factors Snail1 and 2, ZEB1 and
2 and Twist, and nuclear localization of β-catenin.
Down-regulated epithelial proteins include E-cadherin,
ZO-1 (Zona Occludens 1), cytokeratins, claudins, occlu-
dins and basement membrane components collagen IV
and laminin 1. General cell properties induced by the
transition include a change in morphology with the ac-
quisition of spindle shape, loss of epithelial cell polarity
and stress fibers redistribution, resistance to apoptosis
induction and enhanced migratory capability. Resistance
to apoptosis in neoplastic cells undergoing EMT is ac-
companied by the acquisition of a stem cell phenotype
also associated with drug resistance [5]. For the in vivo
experimental confirmation of EMT the introduction of a
cell reporter construct in epithelial cells that subse-
quently continues to be expressed in resulting mesen-
chymal cells has been proposed. Although the
importance of EMT for cancer initiation and progression
has been debated and even completely refuted [6], it
becomes increasingly accepted as a program that pro-
motes invasion and metastasis, a hallmark capability of
cancer [7]. Part of the initial debate was due to semantic
discrepancies and the difficulty to define EMT in vivo.
Markers to serve this purpose have now been proposed
and the situation is more clear with the realization that
EMT in a cancer cell may not be complete and only part
of the EMT markers may be expressed in each instance
[4]. In the process of collective migration, for example,
cells detach from the epithelial site, acquire mesenchy-
mal properties but move en block without losing adhe-
sions between them [8]. The acceptance of EMT as
intrinsic to the malignant process has also been aided by
the discovery that beyond specific EMT-inducing factors
a multitude of general cancer regulating pathways are
important EMT regulators as it will be discussed in fol-
lowing sections.
Ubiquitination and the ubiquitin-proteasome system
(UPS)
Ubiquitin attachment to a target protein is executed
with the help of three types of enzymes. Initially anzyme, E2: ubiquitin conjygating enzyme and E3 ubiquitin ligase. Ub:
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ubiquitin through a thioester bond in an ATP and
Mg++-dependent manner. Then ubiquitin is transferred
to a cysteine residue of an ubiquitin conjugating enzyme
or E2 as a thioester. E2-linked ubiquitin is finally trans-
ferred to a lysine residue of a target protein by an ubi-
quitin ligase or E3 (Figure 1). In the human genome
there exist two E1 enzymes, about 30 to 40 E2 enzymes
and about 600 or more E3 ligases [9].
The two major types of E3 ligases, RING (Really Inter-
esting New Gene) type and HECT (Homologous to
Human Papilloma Virus E6 Carboxyterminal domain)
type, differ in their mode of catalysis but both result in
ubiquitin ligation to the target protein. RING type E3s
are by far more abundant than HECT E3s and comprise
about 95% of human E3s [10], while HECT type E3s
count 28 members in human genome [11]. Ubiquitina-
tion, like other post-translational modifications, is re-
versible and covalently-linked ubiquitin molecules can
be removed by de-ubiquitinating enzymes which pre-
serve cellular ubiquitin reserves and reverse inappropri-
ate ubiquitination [12].
Ubiquitin is a 76 amino-acids protein that has lysine
residues at positions 6, 11, 27, 29, 33, 48 and 63. De-
pending on the lysine that mediates attachment and the
number of ubiquitin molecules that are attached to a
target protein, this protein undergoes different fates. Ly-
sine 48 ubiquitin chains of at least 4 molecules length
lead to the recognition of the target protein by the pro-
teasome and subsequent degradation [13]. Occasionally
lysine 6 and 11-mediated ubiquitin chains have been
observed to signal target protein proteasome degrad-
ation. Lysine 63-mediated ubiquitin attachment leads
less often to proteasome degradation but serves mostly
as signal for autophagy-mediated proteolysis, as well asFigure 2 A conceptual layer overview of cancer EMT. Intermediate tran
co-operate with them in target regulation culminating in down-regulationnon-proteolytic functions such as DNA repair and re-
ceptor kinases endocytosis. Other cell processes in which
ubiquitination participates include DNA transcription
and DNA damage tolerance.
The proteasome is a hollow barrel-shaped multipro-
tein structure of 2.5 MDa comprised of a core particle
(CP or 20S proteasome) flanked in the two sides by a
regulatory particle (RP or 19S proteasome). RP functions
include recognition of the ubiquitinated protein, de-
naturing of the protein, de-ubiquitination which allows
ubiquitin molecules to be recycled and delivery of the
target protein to the CP. CP is made by four rings of
seven member proteins each that are stuck one on the
other. The two peripheral rings are identical and are
called α rings (with sub-units α1 to 7) and the two cen-
tral rings are also identical and are called β rings (with
sub-units β1 to 7). The proteasome possesses three en-
zymatic activities, a trypsin-like (post-basic residues
cleavage) activity, a chymotrypsin-like (post-hydrophobic
residues cleavage) activity and a post-glutamyl (caspase-
like or post-acidic residues cleavage) activity that reside
in sub-units β1, β2, and β5 respectively and degrade tar-
get proteins producing fragments of 4 to 14 amino-acids
[14].
EMT signalling network
A survey of signalling pathways playing a role in EMT
unsurprisingly reveals that they include most major
pathways involved in carcinogenesis. These pathways
signal through transcription factors which in their turn
regulate and are regulated by transcription factors of the
core EMT machinery such as Snail family regulators,
ZEB and Twist (Figure 2). A discussion of pathways that
regulate EMT follows. From this discussion the role of
UPS in EMT regulation becomes evident.scription factors induce or regulate core transcription factors and
of epithelial genes and up-regulation of mesenchymal genes.
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component, is controlled by the Wnt signalling pathway.
The soluble ligand Wnt ligates its cell surface receptor
Frizzled in complex with co-receptor LRP5/6 (Low density
lipoprotein receptor-Related Protein 5/ 6) and activates
intracellular protein Dishevelled (Dvl). Dvl inhibits protein
kinase GSK3β preventing it from phosphorylating β-
catenin. Unphosphorylated β-catenin is freed from the de-
struction complex (see below) to enter the nucleus and
interact with transcription factors of the TCF 4 (T cell fac-
tor 4)/LEF (Lymphoid Enhancer Factor) family to initiate
a transcription program leading to cell proliferation but
also, depending on co-factors, to differentiation or main-
tenance of stem cell dedifferentiated phenotype [15]. In
contrast, in the absence of Wnt, kinase GSK3β remains
active and phosphorylates β-catenin, in co-operation with
kinase CKIα (Casein Kinase Iα). A complex, called de-
struction complex, is formed with the participation of pro-
teins axin, APC (Adenomatous Polyposis Coli) and the
ubiquitin ligase β-TrCP which ubiquitinates β-catenin and
leads to its proteasome degradation. Mutations in APC
are seen in hereditary colorectal cancer syndrome Familial
Adenomatous Polyposis and in the majority of sporadic
colorectal cancer cases and result in constitutive activation
of β-catenin due to failure of its ubiquitination. Among β-
catenin target genes several involved in EMT are included
such as c-myc. Axin2 is also induced by β-catenin and
chaperones kinase GSK3β from the nucleus to the cyto-
plasm, an event that allows transcription modulator Snail
to remain unphosphorylated and active to suppress E-
cadherin transcription [16] (Figure 3). Snail2 (also known
as Slug) and Twist are further regulated by Wnt signalling
[17]. Moreover, other pathways such as FGF co-operate in
Wnt pathway-induced EMT [18].
Transforming Growth Factor β (TGFβ) signalling is
one of the best characterized pathways in carcinogenesisFigure 3 Representation of EMT regulation by β-catenin. β-catenin ind
junctions dissolution makes available further β-catenin molecules for transc
restrains this activity. Fibroblast Growth Factor (FGF) co-operates in β-catenand a dual role is observed with a tumor suppressing ef-
fect during cancer initiation phase followed by a tumor-
promoting effect associated with EMT in more advanced
cancer when the Ras /PI3K/ akt pathway is often con-
comitantly activated and p53 is mutated or disabled [19].
Duration of TGFβ signalling and the cell cycle phase
that the cell transverses may be additional determinants
of TGFβ signalling outcome [20,21]. TGFβ is stored in
the extra-cellular matrix in a latent form [22] and when
released ligates its surface serine/ threonine kinase
receptors TβRI and TβRII which then phosphorylate
and activate Smad2 or 3 proteins. Phosphorylated
Smad2/3 associates with Smad4 and the complex moves
to the nucleus where it acts as transcription co-factor.
TβRI possess further the ability to activate Ras through
adaptor protein ShcA, and proteins Sos1 and Grb2 [23].
All backbone components of TGFβ cascade including
TβRI and TβRII and Smads are regulated by ubiquitina-
tion and proteasome degradation [24]. Members of the
Nedd4 (Neural precursor cells-expressed developmen-
tally down-regulated 4) family of HECT E3 ligases such
as Nedd4-2, Smurf1 and 2, WWP1 and Itch/AIP4 par-
ticipate in this regulation [25]. TGFβ tumor suppressing
or promoting influence is cellular context-dependent
and is mechanistically determined by the presence of
co-factors interacting with Smads mainly on target
promoters leading to activation or suppression of differ-
ent target gene sub-sets. For example, Ets (E26 Trans-
forming Sequence) family transcription factor member
EVI1 (Ecotropic Viral Integration site 1) antagonizes
Smad3-mediated transcription after interaction with it
and PPARγ activation also antagonizes Smad3-mediated
E-cadherin suppression [26]. In contrast, Olig1, a bHLH
(basic Helix Loop Helix) transcription factor co-operates
with Smad2/3 complex in inducing PDGFβ (Platelet
Derived Growth Factor β) transcription.uces transcription of EMT-promoting proteins. Resulting adherens
riptional activity except if ubiquitination and proteasomal degradation
in transcription (shown as a double edge arrow).
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and 2 and Forkhead factors FOXC2 and FOXQ1 result-
ing in E-cadherin suppression [27–31] (Figure 4). EMT
promotion depends on the activation of the Ras pathway
[32] and on neutralization of p53 by mdm2 induction
[33].
TGFβ further promotes EMT by a transcription-
independent way which functions through phosphoryl-
ation of the polarity complex protein Par6 by TβRI (Fig-
ure 4). Phosphorylated Par6 recruits E3 ligase Smurf1
promoting degradation of exchange factor RhoA and
actin depolymerisation leading to tight junction disas-
sembly [34].
A third signalling pathway important in both develop-
ment and EMT involves surface receptor Notch. This re-
ceptor is activated after ligation to the ligand DSL
(Delta/ Serrate/ LAG-2) in Drosophila, and Delta-like 1,
3 and 4 and Jagged-1 and 2 in mammals on the surface
of a neighbouring cell [35,36]. Ligation of Notch by DSL
results in extra-cellular cleavage of Notch near the exter-
nal surface of plasma membrane by ADAM (A Disinte-
grin and Metalloprotease) proteases associated with
ubiquitin-dependent endocytosis of DSL/ extra-cellular
part of Notch into the signalling cell. DSL/ extracellular
domain of Notch interaction uncovers the ADAM cleav-
age site and subsequent endocytosis clears extracellular
domain of Notch from the inter-cellular space that could
neutralize other DSL ligands from interacting with
Notch molecules [37]. A γ-secretase complex cleaves the
intracellular part of Notch (named Notch Intracellular
Domain, NICD) from the transmembrane part (Intracel-
lular and transmembrane part of Notch after ADAMFigure 4 Dual way of EMT regulation by TGF-β. Activation of its recepto
transcription-independent direct effects on cellular junctions.action is called NEXT, Notch Extracellular Truncation)
and NICD is freed to enter the nucleus and join tran-
scription factor CSL [CBF1/ Su(H)/ Lag1 in Drosophila,
named CBF1 (C promoter Binding Factor 1) or RBPJκ
(Recombination signal binding protein for immuno-
globulin kappa J region) in mammals] in transcription
initiation. After NICD binding, RBPJκ is transformed
from a transcription repressor to an activator and pro-
motes transcription of the HES (Hairy and Enhancer of
Split) family of bHLH transcription repressors [38]. Sta-
bility of NICD is regulated by an Fbxw7-containing SCF
(Skp1/ Cul1/ F-box protein/ Rbx1) type E3 ligase which
ubiquitinates it for proteasome degradation.
Notch activation after ligation by Jagged2 increases
cancer cell survival in hypoxic conditions and promotes
EMT [39,40]. This effect is associated with activation of
Akt, Slug up-regulation and E-cadherin suppression. Akt
activation by Notch depends on the transcription of a
soluble factor that acts in an autocrine manner [41]. Al-
though the exact nature of this factor is unknown, it
could be one of the tyrosine kinase receptor ligands that
are known to activate Akt. Induction of FGF2 mediated
by Notch has indeed been documented in endothelial
cells [42]. Additionally, HIF plays a role in Notch
induced Snail and Slug up-regulation and EMT during
hypoxia [43]. TGFβ/ Smad signalling promotes Jagged1-
mediated Notch activation and EMT [44].
Another developmentally important pathway signalling
in EMT is the one of Hedgehog (HH) ligating cell sur-
face receptor Patched. Three Hedgehog ligands exist in
mammals, Sonic, Indian and Desert Hedgehogs (SHH,
IHH and DHH respectively). This ligation relieves thers results in transcription activation through Smads and in
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Smo, analogously to Dvl for the Wnt/ β-catenin path-
way, inhibits phosphorylation of transcription factor Gli
by kinases GSK3, CKI and PKA and frees the transcrip-
tion factor to enter the nucleus and begin transcription.
HH signalling promotes degradation by the ubiquitin-
proteasome system of Gli inhibitor SuFu (Suppressor of
Fused) [45]. In the absence of HH, Smo remains sup-
pressed by Patched and phosphorylation of Gli by
kinases GSK3, CKI and PKA allows its subsequent
ubiquitination by a ubiquitin ligase complex in which
β-TrCP participates and leads to its proteasome deg-
radation. Furthermore, Nedd4 family ligase Itch is
involved in Gli1 degradation [46].
Gli promotes EMT by activating transcription of ZEB2
in normal and neoplastic epithelial esophageal and gas-
tric cells [47,48]. Several mesenchymal genes such as
cadherin N are induced (Figure 5). Matrix Metalloprotei-
nase 11 (MMP-11) is up-regulated by Gli signalling and
facilitates EMT-associated invasion [49]. Wnt pathway is
also induced by up-regulation of Wnt5A [48]. Recipro-
cally, β-catenin induces RNA binding protein CRD-BP
which binds and stabilizes Gli mRNA up-regulating Gli
signalling [50]. β-catenin was shown to be accumulating
in the nucleus in endometrial carcinoma samples with
activated Gli [51]. This effect may be related to the in-
duction of Snail by Gli which suppresses E-cadherin and
thus displaces β-catenin from adherens junctions [52].
In contrast, in colorectal carcinoma, Gli signalling has
been associated with suppression of TCF transcription
in more advanced stages and the interaction of the twoFigure 5 Interrelationship of hedhehog and wnt/ β-catenin pathwayspathways is complex [53]. Colorectal cancer cell lines
transfected with Gli displayed decreased β-catenin tran-
scriptional activity and patient samples showed a reverse
relationship of Gli-β-catenin nuclear accumulation [54].
Activation of Gli depends also on the status of activation
of the Ras/MAPK and PI3K pathways and of p53 which
favour or inhibit Gli. There exists a reciprocal regulation
of Gli on p53 because ligase E3 mdm2 is induced by Gli
[55] (Figure 5). Besides Wnt and Ras/ MAPK, HH also
interconnects with TGFβ in EMT regulation. HH signal-
ling facilitates TGFβ-induced EMT which is reduced
when HH is silenced by siRNA in lung carcinoma cells
[56]. In addition, pharmacologic inhibition of HH in
these cells decreased their migration and invasion [56].
Receptor tyrosine kinase (RTK) pathways including
EGFR (Epidermal Growth Factor Receptor) family,
PDGFR (Platelet Derived Growth Factor Receptor), c-
met (the Hepatocyte Growth Factor Receptor), NGFR
(Nerve Growth Factor Receptor) and FGFR (Fibroblast
Growth Factor Receptor) are implicated in many car-
cinogenesis processes such as apoptosis inhibition, pro-
liferation and angiogenesis as well as in EMT [57]. Two
main downstream pathways are activated by these recep-
tors, the Ras/ Raf/ MEK/ ERK pathway and the PI3K/
Akt pathway. The former culminates to activation of
AP-1 (Activating Protein 1) family transcription factors
while targets of PI3K/ Akt phosphorylation include
apoptotic members of bcl-2 family which are inhibited,
E3 ligases mdm2 and Fbw7 which are protected from in-
hibition, apoptotic transcription factor FoxO, kinase
GSK3β, and caspase 9 which are all inhibited [58]. Thein EMT regulation.
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enhanced cell growth and protein production but also
EMT [59]. Implication in EMT is not surprising given
the close relationship with other pathways such as Wnt/
β-catenin, TGFβ, NF-κB and p53. The JAK/STAT (Janus
Kinases/ Signal Transducers and Activators of Tran-
scription) pathway may also become activated by RTKs
and activation of STAT3 transcription by EGFR signal-
ling leads to Twist activation and EMT in breast cancer
cells [60].
Receptor tyrosine kinase pathways are regulated by the
UPS in multiple ways. Several core components of these
pathways are proteasome substrates. Examples are
kinases Raf [61], ERK1 and 2 [62] and ERK3 [63] of the
Ras branch and the regulatory sub-unit p85 of PI3K [64]
and kinase Akt [65] of the PI3K/ Akt branch. Addition-
ally components of the JAK/ STAT pathway are UPS-
regulated [66]. Tyrosine kinase receptors themselves are
regulated by ubiquitination after ligand binding. Ligand
binding induces ubiquitination with the aid of E3 ligase
Cbl (Casitas B lineage Lymphoma) which then mediates
clathrin-dependent receptor endocytosis through recog-
nition by ubiquitin binding domains in clathrinFigure 6 Schematic representation of EMT regulation by serine/ threo
ubiquitination and proteasome degradation of substrate proteins.associated proteins of clathrin-coated pits [67]. Receptor
endocytosis may lead to receptor degradation or recyc-
ling to the cell surface in order to be available for further
ligand interaction. In other instances signalling may even
continue from internalized receptors in the early endo-
somes. Oncogenic mutations of RTKs may not only in-
crease the activation of receptors but also promote their
surface recycling [68].
Nerve Growth Factor Receptor TrkB induces EMT
with concomitant Twist induction and suppression of E-
cadherin [69]. EMT depends on Twist as Twist knock-
down through RNA interference prevents it, and partially
depends on Snail. Zeb1 plays an important role in TrkB-
induced EMT and promotes metastasis and inhibition of
anoikis probably down-stream of Twist and Snail [70].
Akt was also involved in TrkB-induced EMT in head and
neck squamous carcinomas [71]. Other constituents of
the PI3K pathway such as components of mTORC1 and
2, Raptor and Rictor and loss of phosphatase PTEN are
involved in EMT [72,73]. Additional examples of RTKs
promoting EMT include EGFR [74], Hepatocyte Growth
Factor Receptor c-met [75,76], PDGFR [77] and FGFR
[78].nine kinase GSK3β. Phosphorylation by GSK3β is followed by
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Receptor (ETAR), a G-protein-coupled seven trans-
membrane domain membrane receptor, in an autocrine
and paracrine way. ET-1 signalling contributes to EMT
by activating the PI3K axis, increasing Snail activity and
down-regulating E-cadherin [79]. ET-1 and other neuro-
peptides are involved in progression of prostate cancer
in its castration-resistant phase which is often
chemotherapy-refractory [80]. Neuropeptides signalling
is regulated by the UPS as both the PI3K axis and NF-
κB signalling down-stream of them are UPS targets.GSK3 Kinase, a link between signalling pathways of EMT
and the ubiquitin-proteasome system (UPS)
Serine/ threonine kinase GSK3 has multiple cellular sub-
strates being one of the most versatile cellular kinases
[81]. A major effect of substrates phosphorylation is subse-
quent ubiquitination. GSK3 regulates most of EMT
involved pathways. In the Wnt pathway it promotes base-
line β-catenin degradation until Wnt signalling inhibits it
to allow β-catenin stabilization and transcription (Fig-
ure 6). In TGFβ family signalling, it promotes degradation
of Smads to restrict their transcription activity. Both
Smad1 and Smad3 are GSK3 phosphorylation targets and
thus both the TGFβ and the BMP (Bone Morphogenic
Protein) branches of the pathway are regulated in this
manner [82,83]. In HH signalling, GSK3 promotes Gli
degradation until ligand/ receptor interaction allows Smo
to inhibit it and stabilize Gli for transcription.
Many intermediate transcription factors but also core
transcription factors of EMT undergo regulation by
GSK3 (Figure 6). NF-κB signalling is regulated by GSK3
at the level of co-factor Bcl-3. In addition the alternative
NF-κB pathway is regulated by GSK3 through phosphor-
ylation of precursor p105 which in this case leads to a
partial proteasome-mediated cleavage producing the ma-
ture form NF-κB1 (p50) [84] and the canonical NF-κB
activity is regulated by GSK3 phosphorylation of kinase
IKK [85,86]. Protein RKIP, an NF-κB inhibitor, promotes
GSK3β function, being an additional functional link be-
tween the two EMT regulators [87]. Transcription factor
C-myc stability is regulated by phosphorylations by Akt
and GSK3 followed by ubiquitination [88,89]. HIF1 is
also a target of GSK3 phosphorylation which leads to
VHL-independent proteasome degradation [90,91].
Mdm2 is a GSK3 substrate and its phosphorylation by
the kinase results in activation of the ligase and p53
down-regulation [92]. Ionizing radiation promotes GSK3
phosphorylation at Serine 9 which inhibits activity to-
wards Mdm2 and thus stabilizes p53. PTEN is another
GSK3 substrate after a priming phosphorylation by kin-
ase CK2 [93]. Finally, as mentioned, EMT regulating
transcription factor Snail is a GSK3 substrate. GSK3 isregulated in the transcriptional level by transcription fac-
tor Ets2 down-stream of a mutant activated K-Ras [94].
As a result of its involvement in all these pathways,
GSK3 represents a constitutive suppressor of EMT [95].
Its general mode of action requires a priming phosphor-
ylation of the substrate by another kinase 3 to 4 aminoa-
cids downstream from its own phosphorylation site,
followed by phosphorylation by GSK3 [96]. This double
phosphorylation sites are then recognized by E3 ligases
for ubiquitination and proteasome degradation. Kinase
Akt, an effector of receptor tyrosine kinase pathways is a
GSK3 inhibitor and this is one of Akt actions promoting
EMT (Figure 6). Nevertheless, there exist distinct cellu-
lar pools of GSK3 and not all of them can be inhibited
by Akt. For example, the Axin associated GSK3 which
keeps β-catenin under control is not regulated by Akt.
This represents an additional level of complexity in the
EMT-regulation network.
E3 ligases regulating EMT
E3 ligases of both the RING and the HECT family par-
ticipate in EMT regulation by ubiquitination. Several of
these enzymes are known to regulate other carcinogen-
esis processes because pathways involved in EMT signal-
ling play roles also in these processes and additionally
because these ligases have further substrates that are
involved in carcinogenesis beyond EMT. SCF (Skp1/
Cullin/ F-box) E3 ligases represent a sub-family of RING
type ligases and several members are involved in EMT.
Their general organization comprises a complex of sev-
eral proteins and includes a cullin molecule which is the
scaffold protein of the complex, an F-box protein that
associates through a Skp (S phase kinase-associated pro-
tein) protein with cullin and binds the substrate to be
ubiquitinated and a ROC (also called Rbx) RING finger
protein that binds the complex through cullin and also
binds the ubiquitin-loaded E2 enzyme [97]. The cullin
protein undergoes neddylation, association with the
ubiquitin-like protein NEDD8, an event that facilitates
the assembly of the ligase complex and opens cullin con-
figuration to promote E2 enzyme binding.
βTrCP, a RING type E3 ligase of the SCF sub-type regu-
lates EMT through its involvement in Wnt, HH and NF-
κB cascades and in Snail degradation. βTrCP recognizes
phosphorylated substrates and thus the process of target
destruction is tightly regulated by at least one and some-
times two steps of phosphorylation followed by ubiquiti-
nation. In the Wnt pathway βTrCP inhibits signalling at
base line conditions by degrading β-catenin when this pro-
tein is successively phosphorylated by casein kinase I and
GSK3. In HH signalling, βTrCP participates in the ubiqui-
tination of Gli when the pathway is silent. In both these
pathways kinase GSK3 performs a pre-required phosphor-
ylation step. Proto-oncogene H-Ras is also a target for
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promoting and inhibiting roles in EMT.
Skp2 is the F-box component of another SCF family
RING E3 ligase and is involved in carcinogenesis pro-
cesses through regulation of Cyclin Dependent kinase
inhibitors p27 and p21 [99]. Skp2 promotes TGFβ sig-
nalling, contributing to EMT regulation. It co-operates
also in degradation of mutated non-functional Smad4
promoting TGFβ dependent signalling [100]. This sig-
nalling reciprocally promotes Skp2 nuclear localization
where it is ubiquitinated by E3 ligase APC/C (Anaphase
Promoting Complex/ Cyclosome) for degradation [101].
Fbw7 (F-box and WD repeat domain-containing 7,
also designated Fbxw7 or hCdc4), a third SCF E3 ligase
regulating signal transduction of EMT does so through
its role in degradation of Notch. C-myc is a transcrip-
tional target of Notch and thus it is regulated also indir-
ectly by Fbw7 as the ligase targets both Notch and
presenelin, a component of its activating enzyme γ-
secretase [102].
Fbw7 mutations are synergistic with p53 mutations in
cancer induction in experimental models, given that p53
represents a safeguard mechanism of unopposed c-myc
activity. This is a developmentally preserved mechanism
as, in hematopoiesis for example, Fbw7 preserves
hematopoietic stem cells quiescence while its deletion
results in transient cell growth due to c-myc and cyclin
E (another Fbw7 target) over-activity but finally to stem
cells exhaustion due to p53-induced apoptosis [103].
Analogously, in carcinogenesis concomitant Fbw7 and
p53 mutations would lead to unopposed EMT.
An additional member of the SCF family of ligases
regulating EMT pathways is Cullin 7/ Fbxw8 [104]. Skp1
participates in the ligase complex associating Cullin 7
with Fbxw8 and ROC1 is the E2 recognizing unit. Cullin
7/ Fbxw8 has IRS1 (Insulin receptor substrate 1), a me-
diator of IGF (Insulin-like Growth Factor) pathway, as a
substrate [105]. This pathway, as other RTK pathways,
activates the Ras/ Raf/ MEK/ ERK and the PI3K/ akt
cascades and thus may play a role in EMT in cells that
express the receptor. In addition, cullin 7/ Fbxw8 is fur-
ther implicated in EMT regulation by interfering with
p53 function in a degradation- independent manner
[106].
NEDD4 family of E3 ligases belong to the HECT type
ligases and have nine members in humans, several of
which regulate EMT through their role in TGFβ signal-
ling. All members of the family have three types of con-
served domains. In their amino-terminal part they have
a calcium binding domain designated C2 which mediates
membrane localization after calcium binding. In the cen-
tral part of their molecule NEDD4 ligases harbour two
to four WW domains which recognize substrates and in
the carboxy-terminal end they have the HECT catalyticdomain which has an active cysteine that binds ubiquitin
with a thioester bond before transfer to the substrate
[107]. NEDD4 ligases are regulated by phosphorylation
which may be either activating or inhibitory depending
on the site of the phosphorylation [108,109] and by
auto-ubiquitination [110]. Beyond TGFβ signalling
NEDD4 ligases are involved in EMT by regulating other
pathways. Among these are RTK pathways through ubi-
quitination of several proteins such as receptors them-
selves or down-stream components. NEDD4 promotes
degradation of Vascular Endothelial Growth Factor Re-
ceptor 2 (VEGFR2) [111] and of IGF-1R [112]. NEDD4L
targets the nerve growth factor receptor TrkA [113]. Cbl
family ligases that regulate receptors endocytosis and re-
cycling/ degradation are targets in their turn of NEDD4
family members-mediated ubiquitination [114,115].
Phosphatase PTEN, an inhibitor of the PI3K/ Akt cas-
cade is ubiquitinated by NEDD4 family members and
this modification modulates both its stability and sub-
cellular localization [116–118].
Cbl is a RING E3 ligase that contributes to cell motil-
ity and EMT. Two main mechanisms mediate the influ-
ence of this ligase on EMT. The first is by regulating
signalling of cell surface receptors which, as mentioned,
are ubiquitinated and endocytosed after ligand binding.
The second mechanism involves the targeting of
adhesion-related molecules such as kinase FAK and in-
tegrin α5 by Cbl. Cbl also interferes with the stability of
actin cytoskeleton through its involvement in the ubiqui-
tination of proteins mDab1 (mouse Disabled homologue
1) and WAVE2 (Wiskott-Aldrich syndrome protein ver-
prolin homology 2), proteins participating in G-actin
polymerization [119,120].
Conclusion
This review aims at providing a general overview of the
complexity that underlines the relationship of EMT with
ubiquitination focusing on major UPS regulators of
EMT signal transduction pathways. Examples of com-
mon patterns of UPS regulation in different pathways of
EMT are also provided as well as the inter-connections
of these pathways mediated by UPS components.
Signalling inducing EMT overlaps significantly with
pathways ensuring other carcinogenesis processes such
as proliferation, inhibition of apoptosis, self-sufficiency
for survival and invasion [7]. In addition EMT pheno-
type association with stem cell phenotype [5] and drug
resistance has been increasingly recognized, implying
that all carcinogenesis processes are inter-related and
emblazoned into the same hardware. Numerous inter-
connections ensure the tight control of signals in physio-
logic conditions and the UPS is an integral part.
Of particular interest is the connection of EMT signal-
ling with cell polarity and asymmetric cell division
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relationship of EMT and stemness. In this respect cancer
may be modelled as a disease of increased symmetric
stem cell divisions leading to increased number of neo-
plastic stem cells. Regulators of EMT such as TGFβ and
p53 are shared with asymmetric cell division and this
may have implications for cancer pathogenesis and in-
trinsic ability of metastasis [34,121]. The aforementioned
transcription-independent regulation of Par6 by TGFβ
signalling, besides promoting EMT, also promotes loss
of cell polarity by down-regulating Par complex compo-
nent Par3 and by displacing the complex from the apical
part of the cell membrane to the cytoplasm [122,123].
Cell polarity is important for asymmetric cell divisions
because it helps ensuring the asymmetric inheritance of
proteins determining cell function and fate by the two
daughter cells. An example illustrating this point is
represented by adaptor protein Numb which in asym-
metric divisions segregates in the daughter cell that is
devoid of membrane Par complex. Numb promotes deg-
radation of Notch and Gli by interacting with E3 ligase
Itch and, as a result, the cell that inherit Numb displays
decreased activity of Notch and HH pathways which are
important determinants of stem cell fate but also pro-
moters of EMT [124]. In addition, Numb promotes sta-
bility of p53 by inhibiting ligase Mdm2 [125]. It is
evident that all these functions suppressing EMT would
be lost if asymmetric division is perturbed. In this case,
as a result of collapsed adhesions and polarity, cells
would be left with modified signalling that would favour
motility and metastasis. The implication of these events
in carcinogenesis is that the same cancer-promoting sig-
nals that favour proliferation of cancer stem cells endow
these cells with an inherent metastatic potential by dis-
abling normal control on EMT promoting pathways.Competing interest
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